Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

CrataBL, a lectin and Factor Xa inhibitor, plays a role in blood coagulation and impairs thrombus formation

Full text
Author(s):
Salu, Bruno R. [1] ; Ferreira, Rodrigo S. [1] ; Brito, Marlon V. [1] ; Ottaiano, Tatiana F. [1] ; Cruz, Jose Walber M. C. [1] ; Silva, Mariana Cristina C. [1] ; Correia, Maria Tereza S. [2] ; Paiva, Patricia M. G. [2] ; Maffei, Francisco Humberto A. [3, 4] ; Vilela Oliva, Maria Luiza [1]
Total Authors: 10
Affiliation:
[1] Univ Fed Sao Paulo, Dept Bioquim, BR-04044020 Sao Paulo - Brazil
[2] Univ Fed Pernambuco, Dept Bioquim, BR-50670901 Recife, PE - Brazil
[3] UNESP, Fac Med Botucatu, Dept Cirurgia & Ortopedia, BR-18618970 Botucatu, SP - Brazil
[4] Hosp Santa Catarina, Ctr Estudos & Pesquisas, BR-01310000 Sao Paulo, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Biological Chemistry; v. 395, n. 9, p. 1027-1035, SEP 2014.
Web of Science Citations: 7
Abstract

Arterial thrombosis is an important complication of diabetes and cancer, being an important target for therapeutic intervention. Crataeva tapia bark lectin (CrataBL) has been previously shown to have hypoglycemiant effect and also to induce cancer cell apoptosis. It also showed inhibitory activity against Factor Xa (K-iapp = 8.6 m). In the present study, we evaluated the anti-thrombotic properties of CrataBL in arterial thrombosis model. CrataBL prolongs the activated partial thromboplastin time on human and mouse plasma, and it impairs the heparin-induced potentiation of antithrombin III and heparin-induced platelet activation in the presence of low-dose ADP. It is likely that the dense track of positive charge on CrataBL surface competes with the heparin ability to bind to antithrombin III and to stimulate platelets. In the photochemically induced thrombosis model in mice, in the groups treated with 1.25, 5.0, or 10 mg/kg CrataBL, prior to the thrombus induction, the time of total artery occlusion was prolonged by 33.38%, 65%, and 66.11%, respectively, relative to the time of the control group. In contrast to heparin, the bleeding time in CrataBL-treated mice was no longer than in the control. In conclusion, CrataBL was effective in blocking coagulation and arterial thrombus formation, without increasing bleeding time. (AU)

FAPESP's process: 09/53766-5 - Proteins from plant source with selectivity for inhibition of mammalian enzymes and their role as an anti-inflammatory, antithrombotic, anti-diabetic and anti-tumor agent
Grantee:Maria Luiza Vilela Oliva
Support Opportunities: Research Projects - Thematic Grants